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Crohn’s disease and ulcerative colitis are chronic inflammatory
bowel diseases (IBD) causing severe damage of the luminal
gastrointestinal tract. Differential diagnosis between both
disease entities is sometimes awkward requiring a multifactorial
pathway, including clinical and laboratory data, radiological
findings, histopathology and endoscopy. Apart from disease
diagnosis, endoscopy in IBD plays a major role in prediction of
disease severity and extent (i.e. mucosal healing) for tailored
patient management and for screening of colitis-associated
cancer and its precursor lesions. In this state-of-the-art review,
we focus on current applications of endoscopy for diagnosis
and surveillance of IBD. Moreover, we will discuss the latest
guidelines on surveillance and provide an overview of the most
recent developments in the field of endoscopic imaging and
IBD.
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INTRODUCTION
BOTH CROHN ’S DISEASE and ulcerative colitis arechronic inflammatory bowel diseases (IBD) causing
severe damage of the luminal gastrointestinal tract. Differ-
ential diagnosis between both disease entities is sometimes
awkward including a multifactorial pathway, containing
clinical and laboratory data, radiological findings,
histopathology and endoscopy.1 Apart from disease diag-
nosis, endoscopy in IBD plays a major role in prediction of
disease severity and extent (i.e. mucosal healing) for tailored
patient management and for screening of colitis-associated
cancer and its precursor lesions.
Patients with both Crohn’s disease and ulcerative colitis
are at increased risk of developing colorectal cancer (CRC).
A large meta-analysis described a cumulative incidence for
CRC of 2% at 10 years, 8% at 20 years and 18% after
30 years of disease.2 Therefore, surveillance is recom-
mended, starting in all patients at 8 years with restaging
biopsies and every 1–3 years.3 Presence of specific risk
factors, including active inflammation, anatomical
abnormality (stricture, multiple pseudopolyps), history of
dysplasia, family history of CRC in first-degree relatives and
primary sclerosing cholangitis (PSC) merits annual surveil-
lance intervals. As dysplasia in IBD is often flat and
unequivocal, guidelines recommend obtaining at least 32
random biopsies from all segments of the colon.4 However,
most recent data have shown that the approach of random
biopsies is not effective. In a retrospective analysis of 1010
colonoscopies, van den Broek et al. measured the neoplasia
yield per colonoscopy and the clinical impact per patient of
random biopsies. Four hundred and sixty-six colonoscopies
were carried out for surveillance during which 11 772
random biopsies were taken (median 29). Overall, neoplasia
was detected in 88 colonoscopies, in 85% by targeted
biopsies only and in 9% by both targeted and random
biopsies. Notably, neoplasia was detected in random biop-
sies in only four patients. Of note, two of these patients had
visible neoplasia in previous colonoscopies. Therefore, the
yield of random biopsies was considerably low whereas
neoplasia was macroscopically visible in up to 94% of
colonoscopies.5 Most recently, Watanabe et al.6 presented
the results of a randomized controlled trial carried out at 52
institutions in Japan comparing rates of neoplasia detection
by targeted versus random biopsies in patients with
ulcerative colitis. Patients were randomly assigned to
undergo four random biopsies collected every 10 cm in
addition to targeted biopsies or targeted biopsies from
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locations of suspected neoplasia only. Neoplasia was
detected in 11% of patients in the target group and in 9%
of patients in the random group which was not statistically
significantly different. However, significantly more biopsies
per colonoscopy were collected in the random group (35 vs
3), and even the total examination time was longer (42 vs
27 min). Therefore, the targeted biopsy approach appears to
be non-inferior to random biopsies but more cost- and time-
effective.
Taking the above into consideration, it appears obvious
that there is a strong need for innovation in the field of
endoscopy in IBD. In this state-of-the-art review, we are
therefore focusing on current applications of endoscopy for
diagnosis and surveillance of IBD. Moreover, we will
discuss the latest guidelines for surveillance in IBD and
provide an overview of the most recent and future devel-
opments in the field of endoscopic imaging and IBD.
TRADITIONAL APPROACH: DYE-BASED
CHROMOENDOSCOPY
THE PRINCIPLE OF staining to enhance mucosalsurface pattern morphologies goes back to the 1990s
and therefore represents one of the oldest techniques in
endoscopic imaging.7 The principle of dye-based chro-
moendoscopy, however, still remains the same. Biocompat-
ible dyes are given through the working channel of an
endoscope followed by careful inspection of the mucosa for
suspicious lesions (Fig. 1). Once a lesion is identified,
endoscopic resection should be carried out as redundant
biopsies are causing severe fibrosis, thereby impeding
endoscopic resection strategies.8 Biopsies should only be
taken from lesions which appear unresectable or after
resection from the area surrounding the lesion in order to
rule out additional dysplasia.
One more recently introduced meta-analysis showed a
significant increase in patients with dysplasia when chro-
moendoscopy was used, resulting in an absolute increase of
8%. In addition, the total number of dysplastic lesions was
increased with chromoendoscopy.9 These data have been
seen when both standard definition and high-definition
imaging were compared to chromoendoscopy.
As evidence is suggesting that in the era of modern
endoscopy, most dysplasia in IBD are visible and random
biopsies are not effective in the early detection of dysplasia,
the most recently introduced international consensus state-
ment provides recommendations on surveillance and man-
agement of dysplasia in IBD.9 The SCENIC statement
provides clear evidence that chromoendoscopy rather than
white-light endoscopy (including both standard and high-
definition imaging) is suggested, but also that dye-less
chromoendoscopy techniques, as discussed in the next
paragraph, are currently not recommended to replace the
approach of traditional dye-spraying. Moreover, the con-
sensus recommends that for patients with endoscopically
invisible dysplasia, confirmed by a gastrointestinal pathol-
ogist, referral to an endoscopist with expertise in IBD
surveillance using chromoendoscopy with high-definition
colonoscopy is suggested.
The consensus also provides staining recommendations
for both lesion detection and lesion characterization in IBD
patients. For lesion detection, panchromoendoscopy with
either indigocarmine (0.03%) or methylene blue (0.04%)
with the dyes applied through a water jet channel or biopsy
channel is recommended. For lesion characterization and
delineation of borders, targeted chromoendoscopy is rec-
ommended with either indigocarmine (0.13%) or methylene
blue (0.2%) applied with syringe spray through the biopsy
channel.
Although effective, potential limitations of traditional
chromoendoscopy need to be discussed.10 Chromoen-
doscopy prolongs the endoscopic examination significantly
by a mean of 11 min. Moreover, a distinct learning curve is
required and there are additional costs for dye spraying,
associated with a lack of reimbursement, limiting the wide
application of the technique outside specialized centers.
OPTICAL CHROMOENDOSCOPY IN IBD
TODATE, VARIOUS optical chromoendoscopy systemsare available, consisting of narrow band imaging NBI
Figure 1 Traditional chromoendoscopy in inflammatory
bowel diseases. Panchromoendoscopy, as in this case with
methylene blue, allows for identification of subtle mucosal
lesions.
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(Olympus, Tokyo, Japan), i-scan OE (Pentax, Tokyo,
Japan), CBI (Aohua Photoelectricity, Shanghai, China) and
VIST (Sonoscape, Shenzhen, China). Optical chromoen-
doscopy uses an optical filter placed after the light source,
typically in order to narrow the red light, thereby enhancing
the mucosal vascular pattern morphology.11 To date, only
data for the NBI system for dysplasia detection are
available. However, as all technologies are using a similar
technique, one can potentially anticipate comparable results
for all.
Recently, a prospective, randomized, cross-over study of
42 patients with long-standing ulcerative colitis compared
NBI with conventional colonoscopy for detection of
dysplasia.12 With NBI, 52 suspicious lesions were detected
in 17 patients, compared with 28 suspicious lesions in 13
patients detected during conventional colonoscopy. Targeted
biopsies showed 11 patients with neoplasia. In four patients,
neoplasia was detected by both techniques; in an additional
four patients, neoplasia was detected by NBI only, and in
three patients, only by conventional white-light endoscopy.
Of note, out of 1522 random biopsies carried out, only one
additional patient with dysplasia was diagnosed.
These data were also confirmed by other randomized
controlled studies13,14 while similar results have been shown
when NBI was compared to chromoendoscopy. Most
recently, Bisschops et al.15 carried out a prospective
randomized controlled trial comparing the performance
characteristics of both techniques in patients with long-
standing ulcerative colitis. Overall, no significant difference
was found for neoplasia detection between NBI and
chromoendoscopy with a mean number of neoplastic lesions
per colonoscopy of 0.47 for chromoendoscopy and 0.32 for
NBI. Per-lesion analysis indicated neoplasia detection of
17% for chromoendoscopy and 16% for NBI.
Recently i-scan OE was evaluated for assessment of
inflammatory changes in ulcerative colitis.16,17 The diag-
nostic accuracy of i-scan OE was calculated against
histology using two specific histological scoring systems.
Overall, i-scan OE showed a significant correlation with
histology. Of note, the majority of patients with Mayo grade
0 also showed mucosal abnormalities on i-scan OE. Future
research is currently focusing on the potential of advanced
endoscopic imaging techniques for prediction of disease
severity and extent in IBD and the results of large-scale
multicenter trials are highly anticipated.
DIGITAL CHROMOENDOSCOPY IN IBD
DIGITAL CHROMOENDOSCOPY TECHNIQUES arebased on computed spectral estimation technologies.
Accordingly, no optical filters are required. Various
techniques are available such as Flexible spectral Imaging
Colour Enhancement (FICE) (Fujifilm, Tokyo, Japan), i-
scan (Pentax) and Storz Professional Image Enhancement
System (SPIES) (Storz, Tuttlingen, Germany).
No data are yet available on the usefulness of digital
chromoendoscopy techniques for dysplasia detection in
IBD, although the results of large-scale randomized con-
trolled trials are anticipated.
Two studies have addressed the value of digital chro-
moendoscopy for prediction of disease severity and extent
(i.e. mucosal healing) in IBD. In one study, 78 consecutive
patients with IBD were randomly assigned in a 1:1 ratio to
undergo colonoscopy with high-definition white-light or i-
scan. Digital chromoendoscopy correlated significantly
better with histology for both prediction of disease extent
and severity than white-light imaging.18 The second study
assessed 78 patients with ulcerative colitis by i-scan and
white-light endoscopy.19 It was found that subtle histolog-
ical abnormalities underlying the apparently healed mucosa
in ulcerative colitis could be detected using digital chro-
moendoscopy in the majority of patients with seemingly
complete mucosal healing.
Future studies are now evaluating whether a more
aggressive therapy of IBD patients in the quiescent or mild
phase of the disease might reduce further disease progress
and relapse.
NEW LIGHT FOR IBD: LIGHT-EMITTING DIODE
AND LASER OPTICS
APART FROM XENON light sources, most recentlyintroduced technologies are using laser-based emission
systems (Blue Laser Imaging; Fujifilm) or light-emitting
diode (LED) optics (Blue Light Imaging and Linked Color
Imaging, both Fujifilm) to enhance mucosal surface and
vascular pattern morphologies20 (Figs 2 and 3).
Only one case report has yet described the feasibility of
linked color imaging technology (LCI) for diagnosis of
ulcerative colitis-associated colorectal cancer.21 However,
one most recently published manuscript evaluated the
efficacy of LCI for diagnosing mucosal inflammation in
ulcerative colitis patients.22 Among areas with Mayo
endoscopic subscore of 0, LCI technology significantly
improved the diagnosis of residual inflammation and was
strongly correlated with the histopathological Matts score.
Of note, non-relapse rates also significantly correlated with
LCI classification, but not with the Mayo endoscopic
subscore.
Therefore, LCI may serve as a novel approach for
evaluating colonic mucosal inflammation and for prediction
of clinical outcomes in IBD patients.
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ENDOPATHOLOGY AND COMPUTER-
ASSISTED DIAGNOSIS
THE TERM “ENDOPATHOLOGY” was introducedmany years ago and is now mostly used in relation to
confocal laser endomicroscopy and endocytoscopy. Both
techniques allow for extensive magnification of the mucosal
surface in real time and are therefore not used for detection,
but are more suitable for characterization of lesions.
Technological details of both techniques have been
described in detail elsewhere and are not the scope of the
present review23,24 (Fig. 4).
Confocal laser endomicroscopy
Early data have shown that chromoendoscopy in conjunc-
tion with confocal imaging allows for 4.75-fold more
neoplasia to be found compared to conventional white-light
endoscopy, although up to 50% fewer biopsies were
required.25
Moreover, recent data have highlighted the potential role
of confocal imaging for real time in vivo prediction of
histological changes associated with intestinal disease
activity. In this context, it has been shown that assessment
of crypt architecture and fluorescein leakage showed good
correlations with histological results.26 Of note, half of the
patients with normal mucosa seen on conventional white-
light endoscopy showed acute inflammation on histology,
whereas no patients with normal mucosa or with chronic
inflammation seen on confocal imaging showed acute
inflammation on histology. Similar results have also been
shown for patients suffering from Crohn’s disease.27 More
recent evidence has also highlighted the potential of
confocal imaging for the differential diagnosis of ulcerative
colitis and Crohn’s disease.28 In a prospective study,
Crohn’s patients showed significantly more frequently
discontinuous inflammation, focal cryptitis and discontinu-
ous crypt architectural abnormality than patients with
ulcerative colitis. Conversely, ulcerative colitis was more
often associated with severe, widespread crypt distortion,
decreased crypt density and a frankly irregular surface.
Confocal imaging has also been evaluated for prediction
of disease relapse and clinical outcome in IBD. Buda et al.
first described that patients with inactive disease showed a
Figure 2 Comparison of high-definition white-light imaging and blue light imaging (BLI) for characterization of non-polypoid
colorectal lesion. BLI is enhancing the mucosal vascular pattern morphology, thereby allowing enhanced characterization and
delineation of the lesion.
Figure 3 Linked color imaging (LCI) in ulcerative colitis. Contrary to optical chromoendoscopy techniques LCI is enhancing red
and white contrast, thereby improving visibility without changing the natural color of the tissue.
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significant increase in fluorescein leakage, crypt diameter
and inter-crypt distance compared to patients with quiescent
disease. Based on these findings, the authors composed an
outcome score and were able to predict disease flare during a
12-month follow-up period.29
Most recently, our group has shown that focal cryptitis
and crypt architectural abnormalities are frequently observed
in Crohn’s patients.30 These patients showed an increased
incidence of medical treatment escalation and transmural
lesions at 1-year follow up. Confocal imaging showed
specific features of mucosal inflammation and allowed for
early prediction of relevant clinical outcome parameters.
Further studies should now address whether this promis-
ing prognostic tool could refine the timing of treatment
strategies in patients with Crohn’s disease.
More data have also highlighted the role of functional
tissue diagnosis in IBD based on confocal imaging. First
described in 2007, epithelial gap density in IBD has
meanwhile emerged as an important factor allowing for
prediction of disease relapse but also for prediction of
hospitalization and surgery in patients with IBD.31
Confocal endomicroscopy was recently carried out in
IBD and control patients to determine the relationship
between cell shedding and local barrier dysfunction.32 Most
importantly, patients in clinical remission showing increased
cell shedding were at increased risk of disease relapse within
12 months. Sensitivity, specificity and accuracy for predict-
ing a flare were 63%, 91% and 79%, respectively, and cell
shedding could therefore serve as a potential diagnostic tool
for the management of IBD.
Similarly, Turcotte et al.33 prospectively followed IBD
patients for clinical events including symptom flares,
medication changes, hospitalization, or surgery. Patients
with elevated gap density were at significantly higher risk of
hospitalization or surgery and gap density was identified as a
significant predictor for risk of major events.
More recently, Chang et al.34 carried out a prospective
study of intestinal permeability, measured by confocal
imaging in 110 consecutive subjects with IBD and 22
healthy control patients. Patients with symptomatic IBD had
a significantly higher median confocal leak score than
patients with asymptomatic IBD or controls. Overall, 36%
of patients with IBD in mucosal healing were diagnosed
with increased intestinal permeability. Interestingly, an
increase in intestinal permeability correlated with increased
severity of diarrhea. Therefore, mucosal permeability
beyond mucosal healing might improve further outcomes
of patients with IBD.
Endocytoscopy
Endocytoscopy has been studied in 40 patients with IBD
and allowed for detection and discrimination of single
mucosal inflammatory cells and inflammatory disease
activity.35 Interobserver agreement between two investiga-
tors was substantial (kappa: 0.61–0.78), whereas intraob-
server agreement was substantial to almost perfect (kappa:
0.76–0.88). Concordance between endocytoscopy and
histopathology for grading intestinal disease activity was
measured as 100%. In a pilot study including 26 patients
with ulcerative colitis, Nishiyama et al.36 showed a corre-
lation between endocytoscopy imaging and Matts’
histopathological grade. In the study, patients were classified
into two groups: those with an endocytoscopy score 0–2
(Grade A) and those with an endocytoscopy score of 3–6
(Grade B). With an average post-endocytoscopy
Figure 4 Confocal laser endomicroscopy and endocytoscopy both allow for tissue analysis at the cellular level. Confocal
imaging is more restrictive to architectural details whereas endocytoscopy allows for both characterization of cellular details and
vascular pattern.
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surveillance period of 446 days, only patients with grade B
relapsed. Therefore, endocytoscopy imaging might become
a predictive indicator for relapse of patients with ulcerative
colitis although these initial data need to be confirmed in a
larger cohort setting.
Using endocytoscopy, Nakazato et al.37 recently assessed
histological healing in 64 ulcerative colitis patients in
clinical and endoscopic remission. They found that endo-
cytoscopy can be used to assess histological healing in
patients with ulcerative colitis without the need for biopsy
specimens.
Although both confocal imaging and endocytoscopy
allow for prediction of ultrastructural (i.e. histological)
mucosal changes, interpretation of findings still requires
special expertise and training in the field of histopathology.
Computed assisted diagnosis (CAD) has recently been
developed in conjunction with endocytoscopy, thereby
facilitating interpretation of findings.38,39 Although CAD
has yet only been established for colorectal polyps and
invasive colorectal cancer, it is eventually anticipated that
the CAD algorithm will allow for automated classification of
surface and vascular pattern morphology in IBD patients.
PERSONALIZED MEDICINE AND MOLECULAR
IMAGING
NOWADAYS, MEDICAL MANAGEMENT of patientssuffering from IBD is evolving toward a personalized
model. Therefore, definition of targets that guide intensifi-
cation of therapy is highly warranted.40 In this context,
molecular endoscopic imaging (i.e. in vivo immunohisto-
chemistry) is now rapidly evolving, potentially allowing for
risk stratification, planning and guidance of therapy, mon-
itoring therapeutic efficacy and assessing disease recurrence.
Molecular imaging is based on topical or intravenous
application of specific structures, including antibodies,
peptides, lectins, small molecules or nanoparticles. Typically
labeled with fluorescein isothiocyanate (FITC), simultane-
ous confocal imaging allows for specific identification of
targeted structures such as membrane-bound receptors.
Recent data have already highlighted the potential of
molecular endoscopic imaging for in vivo diagnosis of
Barrett’s esophagus and colorectal polyps.41,42 In addition to
these studies, in 25 patients with Crohn’s disease, our group
has shown that topical administration of a fluorescent-
labeled antibody for molecular membrane tumor necrosis
factor (mTNF) imaging led to detection of intestinal mTNF
(+) immune cells during confocal imaging.43 Patients with
high numbers of mTNF(+) cells showed significantly higher
short-term response rates (92%) at week 12 upon subsequent
anti-TNF therapy as compared to patients with low amounts
of mTNF(+) cells (15%). Of note, the clinical response in
the mTNF(+) patients was sustained over a follow-up period
of 1 year and was associated with mucosal healing observed
at follow-up endoscopy.
These initial data indicate that molecular endoscopic
imaging with fluorescent-labeled antibodies is feasible and
also has the potential to predict therapeutic responses to
biological treatment and can therefore potentially be used
for personalized medicine in IBD. Although these initial
data need to be confirmed, they already provide the first
evidence of the potential of molecular endoscopic imaging
for personalized patient care and individual patient man-
agement.
CONCLUSION
MANAGEMENT OF IBD as a life-long disease is stillchallenging. The introduction of advanced endo-
scopic imaging techniques has led to an adaption of current
guidelines. Most dysplasia in IBD is visible and therefore
the recommendation for random biopsies during surveil-
lance appears obsolete. Instead, high-definition endoscopes
should be used in conjunction with traditional dye-spraying.
Table 1 Summary of potential advantages and disadvantages of endoscopic imaging in inflammatory bowel diseases
Technique Dysplasia detection Prediction of
mucosal healing
Prediction of
clinical outcome
Prediction
of relapse
Prediction of
therapeutic response
White-light +    
Traditional chromoendoscopy ++    
Optical chromoendoscopy  +   
Digital chromoendoscopy  +   
LED-based imaging  +  + 
Confocal imaging + ++ ++ ++ 
Endocytoscopy  ++  + 
Molecular imaging     +
(++) good evidence; (+) weak evidence; () not effective; no data.
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Although it might appear surprising that modern image-
enhanced endoscopy systems are not able to improve
dysplasia detection in IBD, one might explain this finding
with the technical principle of dye-less chromoendoscopy
techniques. The principle of these techniques mostly relies
on visualization of mucosal vascular pattern morphology.
However, in IBD, the vascular pattern morphology is
generally disturbed by chronic inflammation. Therefore, it
might appear obvious that technologies enhancing vascular
pattern morphology for detection of dysplastic lesions are
not effective in chronic inflammatory conditions. On the
contrary, new LED-based systems have now been intro-
duced, focusing more on general contrast enhancement of
the luminal gastrointestinal tract. Data regarding the effec-
tiveness of this new technology for enhanced dysplasia
detection in IBD are therefore highly warranted.
In the rare case of patients with endoscopically invisible
dysplasia identified with random biopsies, confirmation of
dysplasia by a second gastrointestinal pathologist is advised,
followed by referral of the patient to an endoscopist with
expertise in IBD surveillance using chromoendoscopy and
high-definition imaging.
Apart from dysplasia detection, the role of endoscopy is
rapidly evolving for prediction of clinical outcome and
relapse of IBD patients. In this context, modern image-
enhanced endoscopy systems have already shown their
potential and we are expecting the long-term results of
ongoing studies within the upcoming 2 years.
Management of IBD patients is evolving toward person-
alized medicine with the aim of reducing side-effects, costs
and greater effectiveness of treatment. In this context, early
data have already shown the potential of molecular
endoscopic imaging for prediction of therapeutic responses
to anti-TNF antibody therapy. Although the safety of topical
application and intravenous injection of fluorescence-
labeled structures in human patients have already been
described, it appears obvious that additional studies
addressing the safety of molecular endoscopic imaging are
needed. However, even taking into account the recent
progress in the field of computer-assisted diagnosis, one
could anticipate that prediction of therapeutic response
based on molecular endoscopic imaging might soon become
a valuable tool once the safety questions have been fully
answered.
Taken together, the role of advanced endoscopic imaging
in IBD is rapidly evolving (Table 1). Starting with surveil-
lance and dysplasia detection many years ago, endoscopy
today is evaluated more for prediction of clinically relevant
outcome parameters and for guidance of pharmaceutical
therapies.
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